Neuroepithelioma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Neuroepithelioma Market Outlook
Thelansis’s “Neuroepithelioma Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024
To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Neuroepithelioma treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
Neuroepithelioma Overview
Neuroblastoma
is a malignant tumor that arises from neural crest cells, which give rise to
the sympathetic nervous system, and occurs mainly in children. The prognosis of
neuroblastoma is affected by various genetic anomalies, such as amplification
of the oncogene MYCN, numerical abnormalities of chromosomes and segmental
chromosomal anomalies (including loss from 1p, from 11q, or gains of 17q).
Diagnosis is based on elevated metabolites of urinary catecholamines and
imaging of the initial tumor by ultrasound, brain scan, or MRI. MIBG
scintigraphy and medullary analysis are useful for detecting metastases.
Nephroblastoma is a differential diagnosis. Bone pain and limp can be
misinterpreted as synovitis of the hip, and bilateral peri-orbital hematomas
should not be mistaken for maltreatment. The prognosis of neuroblastoma is poor
for approximately 60% of children over one year of age who present with
metastatic disease at diagnosis, even with intensive treatment. The five-year
survival rate for children over one year of age ranges from 95% for some
localized tumors to 30% in cases of metastatic neuroblastoma.
Geography coverage:
G8 (United States, EU5 [France,
Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust
research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal
articles, third-party research databases)
Deliverables format and
updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated
dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant
support
*As per Thelansis’s policy, we
ensure that we include all the recent updates before releasing the report
content and market model.
Salient features of Market
Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated
through the top-down sales methodology
- Covers clinically and commercially-relevant patient
populations/ line of therapies
- Annualized drug-level sales and patient share
projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management
strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of
incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and
patient share?
- Which events will have the greatest impact on the
market’s trajectory?
- What insights do interviewed experts provide on
current and emerging treatments?
- Which pipeline products show the most promise, and
what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for
target profiles?
- What key regulatory and payer requirements must be
met to secure drug approval and favorable market access?
- and more…
Comments
Post a Comment